MADRIGAL PHARMACEUTICALS, INC. (MDGL) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US5588681057
Price
460.01 USD
Market cap
10.63 bn USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–
MADRIGAL PHARMACEUTICALS, INC. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 958.40 m USD |
| Operating income | -300.10 m USD |
| EBIT | -303.34 m USD |
| Net income | -288.28 m USD |
| Diluted EPS – continuing operations | -12.85 USD |
Full history since 2001, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About MADRIGAL PHARMACEUTICALS, INC.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
More stocks
- Fidelity National Financial, Inc. (FNF)
- Goertek Inc (002241.SZ)
- Absa Group Ltd (ABG.JO)
- Eiffage SA (FGR.PA)
- Yara International ASA (YAR.OL)
- Petro Rio S.A. (PRIO3.SA)
- Tele2 AB (TEL2 B.ST)
- FactSet (FDS)
- Kikkoman Corp (2801.T)
- Shizuoka Financial Group Inc (5831.T)
- Inner Mongolia Yitai Coal Co Ltd (900948.SS)
- Suzano Papel e Celulose SA ADR (SUZ)
Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.